Technology informed by unparalleled Decentralized Trials (DCT) operational experience and delivered at global scale.
Keynote Presentation:
November 15, 9am ET / 1400 GMT
DCTs deliver big ROI: How hybrid approaches deliver measurable benefits to sponsors
Decentralized clinical trials deliver time and cost efficiencies at nearly every point of the clinical research journey. In this session, you'll learn about 14 value measures that IQVIA analysts used to showcase the positive trends and impacts seen by using a combination of DCT technologies and in-home support to streamline trial operations.
But sponsors don't have to overhaul their entire protocol to reap significant benefits. Strategic deployment of tools like eConsent and eCOA can on their own strengthen engagement, workflow efficiencies and trial outcomes, IQVIA leaders will show through case studies and more.
Bhausaheb Patil Senior Director, Head of Business Operations, IQVIA Decentralized Trials |
|
Karen Maduschke Senior Director & General Manager, IQVIA Complete Consent |
Technology informed by unparalleled Decentralized Trials (DCT) operational experience and delivered at global scale.
Deliver eConsent to sites and study participants around the globe with confidence
Bring trials directly to patients to improve access and engagement, increase quality and shorten timelines.
Ease the burden on your sites and make it easier and more appealing for patients to enroll and remain engaged.
Combine data science, technology, and analytics driven by artificial intelligence to support new efficiencies and business insights -- without additional capital investment.
Explore our end-to-end, full service clinical development capabilities including Therapeutics expertise, Development Planning, Phase I early clinical development, Phase IIb/III and Phase IV Trials, Regulatory Submission and Post-Launch Studies.